Pirnay JP, Djebara S, Steurs G, Griselain J, Cochez C, De Soir S, et al
Initial thoughts by food companies in response to this [weight-loss drugs] is that this is a manageable threat because the supply constraints of this new class of drugs is so limited there is no way a large percentage of the population will take it up. It was expected that only 1%-2% of the US adult population would be taking these drugs by 2030
Wvan der Zanden R, De Vries F, Lalmohamed A, et al
however, after the appearance of prospective randomized studies that indicated an increase in the incidence of breast cancer, the establishment of this therapy has been adjusted to the presence of certain risk factors, symptoms, and the evolution of patients (Zhao and Brinton, 2006)